Morning Movers
Watch us on YouTube Live at 8:30AM EST

TSLA.NQ 2.93%
Tesla Inc – Trading higher early on after data showed the company delivered a record 241,300 vehicles in Q3, beating analyst estimates of 229,242 vehicles on growing demand for its entry-level Model 3. Figures show TSLA has weathered a chip shortage much better than its peers; General Motors GM.N, Honda and other bigger rivals posted declines in Q3 U.S. sales.

MRK.NY 2.70%
Merck & Co – Back on watch after Friday’s rally that followed data on the company’s experimental covid-19, oral antiviral medication that showed a 50% decline in hospitalizations and deaths in a recent study.

PLTR.NY -1.36%
Palantir Technologies – The National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS) has extended its current contract with Palantir to support the National COVID Cohort Collaborative (N3C) and its data enclave is an indefinite delivery indefinite quantity (IDIQ) contract with a total potential value of $59.5m over two years, with an initial task order for $7.9m over the first five months.

Vaccine Stocks – Under pressure as a group for the second straight session premarket as we saw Friday, following the MRK oral treatment data. JNJ planning to ask FDA to authorize a 3rd booster shot of its vaccine this week. MRNA, BNTX, NVAX, DVAX, PFE

Airline Stocks – Multiple upgrades on the group today. Delta reinstated its original third-quarter revenue forecast, after cutting it a month ago. The company said ticket sales stabilized and then improved last quarter, and the airline is also expecting 2022 domestic bookings to surpass pre-pandemic levels. LUV upgraded by Barclay’s to “Overweight” from “Equal Weight” DAL, LUV, AAL, UAL, SAVE, ALK

BABA.NY -2.22%
Alibaba Group Holdings – Set to open at a fresh, multi-year low this morning down 2% premarket. Mizuho analysts have become the latest to slap Chinese tech stocks with downgrades, cutting Alibaba’s PT on further Chinese crackdown risks.

OPGN.NQ 28.99%
Opgen Inc – Announced today that it has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market the Acuitas® AMR Gene Panel, and is finalizing preparations for its swift commercial launch in the U.S.

XENE.NQ 89.49%
Xenon Pharmaceuticals – Shares are trading sharply higher premarket after co reports positive mid-stage trial data for it’s focal epilepsy treatment.

JSPR.NQ 25.00%
Jasper Therapeutics – Sharply higher after AMGN reported a 7.4% stake in the recent SPAC conversion.

Leave a Reply

Your email address will not be published.